The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials
The impacts of subcutaneous Lixisenatide on body weight in patients with type 2 DM, remain inadequately understood; consequently, this systematic review and meta-regression analysis of randomized controlled trials (RCTs) was conducted to evaluate the influence of subcutaneous Lixisenatide administra...
Gespeichert in:
| Veröffentlicht in: | Diabetes research and clinical practice 2024-04, Vol.210, p.111617, Article 111617 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 111617 |
| container_title | Diabetes research and clinical practice |
| container_volume | 210 |
| creator | Sheng, Lei Deng, Meixian Li, Xin Wan, Huan Lei, Changjiang Prabahar, Kousalya Hernández-Wolters, Benjamin Kord-Varkaneh, Hamed |
| description | The impacts of subcutaneous Lixisenatide on body weight in patients with type 2 DM, remain inadequately understood; consequently, this systematic review and meta-regression analysis of randomized controlled trials (RCTs) was conducted to evaluate the influence of subcutaneous Lixisenatide administration on BW and BMI values in individuals with Type 2 diabetes.
A comprehensive literature search was conducted across four databases, spanning from their inception to February 2023. We computed effect sizes employing the random-effects model and reported results in terms of weighted mean differences (WMD) along with their corresponding 95% confidence intervals (CI).
23 articles with 26 RCT arms were included in the meta-analysis. The combined findings from a random-effects model demonstrated a significant reduction in body weight (WMD: −0.97 kg, 95 % CI: −1.10, −0.83, p |
| doi_str_mv | 10.1016/j.diabres.2024.111617 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2958295508</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168822724001013</els_id><sourcerecordid>2958295508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c313t-79014ab7fb1311ddb730bc256e1eb521286c843977b3cda257826858b77624df3</originalsourceid><addsrcrecordid>eNqFkU2P0zAQhi3Eii0LPwHkI5cUfySxwwWtlk-pqz2wnC1_TKirJC62Qyn_h_-5LilcOVgz8jzj8bwvQi8oWVNC29e7tfPaREhrRli9ppS2VDxCKyoFqyRj4jFaFU7-yS_R05R2hJCW180TdMll3ZG6Yyv0-34LGPoebMahx2k2ds56gjAnvPE_fYJJZ-8AhwkfwH_bZjyElLCf8L4UYMoJH3ze4nzcA2b4XfkUZEj4FobB5zm9wV-OKcNYYIsj_PBwwHpypZ51dT3p4Zh8Oo2O5TaM_hc4bMOUYxiGkubo9ZCeoYu-BHh-jlfo64f39zefqs3dx88315vKcspzJTpCa21Ebyin1DkjODGWNS1QMA2jTLZW1rwTwnDrNGuEZK1spBGiZbXr-RV6tby7j-H7DCmr0SdbNlkUUaxrZDkNkQVtFtTGokeEXu2jH3U8KkrUySG1U2eH1MkhtThU-l6eR8xmBPev668lBXi7AFAWLXJFlWzR2YLzsbikXPD_GfEAqXSnPw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2958295508</pqid></control><display><type>article</type><title>The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Sheng, Lei ; Deng, Meixian ; Li, Xin ; Wan, Huan ; Lei, Changjiang ; Prabahar, Kousalya ; Hernández-Wolters, Benjamin ; Kord-Varkaneh, Hamed</creator><creatorcontrib>Sheng, Lei ; Deng, Meixian ; Li, Xin ; Wan, Huan ; Lei, Changjiang ; Prabahar, Kousalya ; Hernández-Wolters, Benjamin ; Kord-Varkaneh, Hamed</creatorcontrib><description>The impacts of subcutaneous Lixisenatide on body weight in patients with type 2 DM, remain inadequately understood; consequently, this systematic review and meta-regression analysis of randomized controlled trials (RCTs) was conducted to evaluate the influence of subcutaneous Lixisenatide administration on BW and BMI values in individuals with Type 2 diabetes.
A comprehensive literature search was conducted across four databases, spanning from their inception to February 2023. We computed effect sizes employing the random-effects model and reported results in terms of weighted mean differences (WMD) along with their corresponding 95% confidence intervals (CI).
23 articles with 26 RCT arms were included in the meta-analysis. The combined findings from a random-effects model demonstrated a significant reduction in body weight (WMD: −0.97 kg, 95 % CI: −1.10, −0.83, p < 0.001) and BMI (WMD: −0.48 kg/m2, 95 % CI: −0.67, −0.29, P < 0.001) after subcutaneous administration of Lixisenatide. Furthermore, a more pronounced reduction in body weight was discovered in RCTs lasting less than 24 weeks (WMD: −1.56 kg, 95 % CI: −2.91, −0.20, p < 0.001), employing a daily dosage of subcutaneous Lixisenatide lower than 19 µg per day (WMD: −1.94 kg, 95 % CI: −2.54, −1.34, p < 0.001) and with a mean participant age of 60 years or more (WMD: −1.86 kg, 95 % CI: −3.16, −0.57, p = 0.005).
Lixisenatide was found to significantly decrease BW and BMI in patients with type 2 DM and could be considered as a therapeutic option for those suffering from weight gain caused by other anti-diabetic agents. However, while prescribing Lixisenatide, careful consideration of patient-specific factors is recommended.</description><identifier>ISSN: 0168-8227</identifier><identifier>ISSN: 1872-8227</identifier><identifier>EISSN: 1872-8227</identifier><identifier>DOI: 10.1016/j.diabres.2024.111617</identifier><identifier>PMID: 38490492</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>Body Weight ; Diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Glucagon-Like Peptide-2 Receptor ; Humans ; Meta-analysis ; Middle Aged ; Obesity ; Peptides ; Randomized Controlled Trials as Topic ; RCT ; Subcutaneous Lixisenatide ; Weight ; Weight Loss</subject><ispartof>Diabetes research and clinical practice, 2024-04, Vol.210, p.111617, Article 111617</ispartof><rights>2024 Elsevier B.V.</rights><rights>Copyright © 2024 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c313t-79014ab7fb1311ddb730bc256e1eb521286c843977b3cda257826858b77624df3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.diabres.2024.111617$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38490492$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sheng, Lei</creatorcontrib><creatorcontrib>Deng, Meixian</creatorcontrib><creatorcontrib>Li, Xin</creatorcontrib><creatorcontrib>Wan, Huan</creatorcontrib><creatorcontrib>Lei, Changjiang</creatorcontrib><creatorcontrib>Prabahar, Kousalya</creatorcontrib><creatorcontrib>Hernández-Wolters, Benjamin</creatorcontrib><creatorcontrib>Kord-Varkaneh, Hamed</creatorcontrib><title>The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials</title><title>Diabetes research and clinical practice</title><addtitle>Diabetes Res Clin Pract</addtitle><description>The impacts of subcutaneous Lixisenatide on body weight in patients with type 2 DM, remain inadequately understood; consequently, this systematic review and meta-regression analysis of randomized controlled trials (RCTs) was conducted to evaluate the influence of subcutaneous Lixisenatide administration on BW and BMI values in individuals with Type 2 diabetes.
A comprehensive literature search was conducted across four databases, spanning from their inception to February 2023. We computed effect sizes employing the random-effects model and reported results in terms of weighted mean differences (WMD) along with their corresponding 95% confidence intervals (CI).
23 articles with 26 RCT arms were included in the meta-analysis. The combined findings from a random-effects model demonstrated a significant reduction in body weight (WMD: −0.97 kg, 95 % CI: −1.10, −0.83, p < 0.001) and BMI (WMD: −0.48 kg/m2, 95 % CI: −0.67, −0.29, P < 0.001) after subcutaneous administration of Lixisenatide. Furthermore, a more pronounced reduction in body weight was discovered in RCTs lasting less than 24 weeks (WMD: −1.56 kg, 95 % CI: −2.91, −0.20, p < 0.001), employing a daily dosage of subcutaneous Lixisenatide lower than 19 µg per day (WMD: −1.94 kg, 95 % CI: −2.54, −1.34, p < 0.001) and with a mean participant age of 60 years or more (WMD: −1.86 kg, 95 % CI: −3.16, −0.57, p = 0.005).
Lixisenatide was found to significantly decrease BW and BMI in patients with type 2 DM and could be considered as a therapeutic option for those suffering from weight gain caused by other anti-diabetic agents. However, while prescribing Lixisenatide, careful consideration of patient-specific factors is recommended.</description><subject>Body Weight</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Glucagon-Like Peptide-2 Receptor</subject><subject>Humans</subject><subject>Meta-analysis</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Peptides</subject><subject>Randomized Controlled Trials as Topic</subject><subject>RCT</subject><subject>Subcutaneous Lixisenatide</subject><subject>Weight</subject><subject>Weight Loss</subject><issn>0168-8227</issn><issn>1872-8227</issn><issn>1872-8227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2P0zAQhi3Eii0LPwHkI5cUfySxwwWtlk-pqz2wnC1_TKirJC62Qyn_h_-5LilcOVgz8jzj8bwvQi8oWVNC29e7tfPaREhrRli9ppS2VDxCKyoFqyRj4jFaFU7-yS_R05R2hJCW180TdMll3ZG6Yyv0-34LGPoebMahx2k2ds56gjAnvPE_fYJJZ-8AhwkfwH_bZjyElLCf8L4UYMoJH3ze4nzcA2b4XfkUZEj4FobB5zm9wV-OKcNYYIsj_PBwwHpypZ51dT3p4Zh8Oo2O5TaM_hc4bMOUYxiGkubo9ZCeoYu-BHh-jlfo64f39zefqs3dx88315vKcspzJTpCa21Ebyin1DkjODGWNS1QMA2jTLZW1rwTwnDrNGuEZK1spBGiZbXr-RV6tby7j-H7DCmr0SdbNlkUUaxrZDkNkQVtFtTGokeEXu2jH3U8KkrUySG1U2eH1MkhtThU-l6eR8xmBPev668lBXi7AFAWLXJFlWzR2YLzsbikXPD_GfEAqXSnPw</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Sheng, Lei</creator><creator>Deng, Meixian</creator><creator>Li, Xin</creator><creator>Wan, Huan</creator><creator>Lei, Changjiang</creator><creator>Prabahar, Kousalya</creator><creator>Hernández-Wolters, Benjamin</creator><creator>Kord-Varkaneh, Hamed</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202404</creationdate><title>The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials</title><author>Sheng, Lei ; Deng, Meixian ; Li, Xin ; Wan, Huan ; Lei, Changjiang ; Prabahar, Kousalya ; Hernández-Wolters, Benjamin ; Kord-Varkaneh, Hamed</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c313t-79014ab7fb1311ddb730bc256e1eb521286c843977b3cda257826858b77624df3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Body Weight</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Glucagon-Like Peptide-2 Receptor</topic><topic>Humans</topic><topic>Meta-analysis</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Peptides</topic><topic>Randomized Controlled Trials as Topic</topic><topic>RCT</topic><topic>Subcutaneous Lixisenatide</topic><topic>Weight</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sheng, Lei</creatorcontrib><creatorcontrib>Deng, Meixian</creatorcontrib><creatorcontrib>Li, Xin</creatorcontrib><creatorcontrib>Wan, Huan</creatorcontrib><creatorcontrib>Lei, Changjiang</creatorcontrib><creatorcontrib>Prabahar, Kousalya</creatorcontrib><creatorcontrib>Hernández-Wolters, Benjamin</creatorcontrib><creatorcontrib>Kord-Varkaneh, Hamed</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes research and clinical practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sheng, Lei</au><au>Deng, Meixian</au><au>Li, Xin</au><au>Wan, Huan</au><au>Lei, Changjiang</au><au>Prabahar, Kousalya</au><au>Hernández-Wolters, Benjamin</au><au>Kord-Varkaneh, Hamed</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials</atitle><jtitle>Diabetes research and clinical practice</jtitle><addtitle>Diabetes Res Clin Pract</addtitle><date>2024-04</date><risdate>2024</risdate><volume>210</volume><spage>111617</spage><pages>111617-</pages><artnum>111617</artnum><issn>0168-8227</issn><issn>1872-8227</issn><eissn>1872-8227</eissn><abstract>The impacts of subcutaneous Lixisenatide on body weight in patients with type 2 DM, remain inadequately understood; consequently, this systematic review and meta-regression analysis of randomized controlled trials (RCTs) was conducted to evaluate the influence of subcutaneous Lixisenatide administration on BW and BMI values in individuals with Type 2 diabetes.
A comprehensive literature search was conducted across four databases, spanning from their inception to February 2023. We computed effect sizes employing the random-effects model and reported results in terms of weighted mean differences (WMD) along with their corresponding 95% confidence intervals (CI).
23 articles with 26 RCT arms were included in the meta-analysis. The combined findings from a random-effects model demonstrated a significant reduction in body weight (WMD: −0.97 kg, 95 % CI: −1.10, −0.83, p < 0.001) and BMI (WMD: −0.48 kg/m2, 95 % CI: −0.67, −0.29, P < 0.001) after subcutaneous administration of Lixisenatide. Furthermore, a more pronounced reduction in body weight was discovered in RCTs lasting less than 24 weeks (WMD: −1.56 kg, 95 % CI: −2.91, −0.20, p < 0.001), employing a daily dosage of subcutaneous Lixisenatide lower than 19 µg per day (WMD: −1.94 kg, 95 % CI: −2.54, −1.34, p < 0.001) and with a mean participant age of 60 years or more (WMD: −1.86 kg, 95 % CI: −3.16, −0.57, p = 0.005).
Lixisenatide was found to significantly decrease BW and BMI in patients with type 2 DM and could be considered as a therapeutic option for those suffering from weight gain caused by other anti-diabetic agents. However, while prescribing Lixisenatide, careful consideration of patient-specific factors is recommended.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>38490492</pmid><doi>10.1016/j.diabres.2024.111617</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8227 |
| ispartof | Diabetes research and clinical practice, 2024-04, Vol.210, p.111617, Article 111617 |
| issn | 0168-8227 1872-8227 1872-8227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2958295508 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Body Weight Diabetes Diabetes Mellitus, Type 2 - drug therapy Glucagon-Like Peptide-2 Receptor Humans Meta-analysis Middle Aged Obesity Peptides Randomized Controlled Trials as Topic RCT Subcutaneous Lixisenatide Weight Weight Loss |
| title | The effect of subcutaneous Lixisenatide on weight loss in patients with type 2 Diabetes Mellitus: Systematic review and Meta-Analysis of randomized controlled trials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T21%3A55%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effect%20of%20subcutaneous%20Lixisenatide%20on%20weight%20loss%20in%20patients%20with%20type%202%20Diabetes%20Mellitus:%20Systematic%20review%20and%20Meta-Analysis%20of%20randomized%20controlled%20trials&rft.jtitle=Diabetes%20research%20and%20clinical%20practice&rft.au=Sheng,%20Lei&rft.date=2024-04&rft.volume=210&rft.spage=111617&rft.pages=111617-&rft.artnum=111617&rft.issn=0168-8227&rft.eissn=1872-8227&rft_id=info:doi/10.1016/j.diabres.2024.111617&rft_dat=%3Cproquest_cross%3E2958295508%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2958295508&rft_id=info:pmid/38490492&rft_els_id=S0168822724001013&rfr_iscdi=true |